Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?

July 6, 2024

Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.

More To Explore

Peak XV trims stake in Zinka Logistics in Rs 302 crore bulk deal; ADIA, MIT among buyers

Zinka Logistics Solutions (BlackBuck) saw a Rs 302 crore block deal as Peak XV Partners trimmed stake. ADIA, MIT, and ICICI Prudential emerged as key

June 3, 2025

Rs 804 crore worth block deals in Aptus Value Housing. Morgan Stanley, SBI MF are among buyers

Aptus Value Housing block deal: Aptus Value Housing Finance witnessed Rs 804 crore worth of block deals on Tuesday. Key buyers included Morgan Stanley, East

June 3, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003